InsidersTradesSigma
Follow the Aegerion Pharmaceuticals, Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on US US, under the authority of SEC (Form 4). Market capitalisation: €1.8bn. The latest transaction was reported on 29 January 2016 (Levée d'options). Among the most active insiders: SMITH SANDFORD D. The full history is free.
Analysts rate Aegerion Pharmaceuticals, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$57.10.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
2 of 2 declarations
Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for rare diseases. It is listed on NASDAQ under the ticker AEGR.